Spatial Pharmacokinetic and Pharmacodynamic Modeling in Airway Mucus.

ABSTRACT:

Background and objectives

Diseases such as cystic fibrosis (CF) and non-CF bronchiectasis can cause extensive mucus formation in the lung, which may affect drug distribution and effects. As such, quantitative understanding of drug distribution in mucus may guide treatment optimization. Here, we aimed to develop a modeling framework to evaluate spatial distribution of drugs in mucus with CF as a proof of concept. In a case study, we demonstrated how spatial PK models can be used to predict spatial antimicrobial pharmacodynamics (PD).

Methods

A spatial pharmacokinetic (PK) model in mucus was developed using discretized partial differential equations. Hypothetical drugs with realistic ranges for molecule/particle size (radius, r), mucin binding affinity, and half-lives were use

SUBMITTER: Guo Y 

PROVIDER: S-EPMC12715044 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature